Aug 03, 2023 / 02:00AM GMT
Michael Baker - Arovella Therapeutics Limited - CEO & MD
Great. Thanks very much, Christy, and thanks very much to the organizers for putting the events, of course, big thank you to everybody for taking the time to listen in today, we're delighted to have you here. And so yes, that's exactly what we're talking about Arovella Therapeutics. For those of you that don't know. I said ticker is ALI. and we are a biotechnology company focused on the battle against cancer. I will be making forward-looking statements, so please do take note of the disclaimers.
Now I'd like to start with the highlights of the Company and what we're working on. We determine the invariant natural killer T cell platform, which is a mouthful, and I'll unpack what that means in a moment. And for short, we call it iNKT cells, and we're using that to develop initially treatments for blood cancers.
But as Christy just mentioned, also looking to tactical a range of solid tumors as we build out from behind. So our lead product is ALA-101 that's going after very specific form of blood cancer leukemia or lymphoma. That
Arovella Therapeutics Ltd at TechKnow Investor Conference - Melbourne Transcript
Aug 03, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers